We have two ongoing projects:
1: Screening for new restriction restriction enzymes:
This project has yielded and is yielding several interesting new restriction enzymes among which one is patented (CspCI, InternationalPatentOffice. 2005,WO200594516A).
For this project we have collaborated for many years with the leading company in restriction enzymes: New England Biolabs in the USA.
Below some of our findings (on the market, commercialized by New England Biolabs):
BceAI, BfuAI, BfuCI, BpuEI, BseYI, BspCNI and CspCI
And many not yet on the market under characterization:
2: Research and development of affordable anti HIV/AIDS medicines for developing countries based on natural products isolated from Cameroon’s plant biodiversity:
Just two years into this project, we have successfully identified several plants extracts with inhibitory activity against HIV in cell culture with no toxicity. IC50 range in the 2µg/ml of crude extract.
For this project we received funding from two Foundations and we are collaborating with two companies: Esperanza Medicines Foundation and Inpheno, both in Switzerland.
We have submitted several projects for funding and we are awaiting the outcome.